QNCX
Quince Therapeutics, Inc.
0.87
USD
This page is just a preview of the data found in TrendSpider’s full version
Quince Therapeutics, Inc. stock is down -7.27% since 30 days ago. The next earnings date is Mar 13, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 19 December’s closed higher than November.
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor.
